BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGreat news! On May 18, Bio-Thera's recombinant humanized anti-VEGF monoclonal antibody injection (BAT1706 ) was approved for clinical trials by the China Food and Drug Administration (CFDA), marking our second approval for biosimilar clinical trials this year. BAT1706 is a bevacizumab biosimilar ind...
On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706 (a bevacizumab biosimilar), which is currently carrying out its global development plan, has enrolled its first two healthy subjects in New Zealand. This is the first clinical ...
